Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-3 peptide-pulsed autologous peripheral blood mononuclear cells + Melan-A peptide-pulsed autologous peripheral blood mononuclear cells
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intradermal
01
Overview
This therapeutic agent is an autologous cellular immunotherapy designed to treat malignancies expressing specific tumor-associated antigens, primarily metastatic melanoma. The process involves harvesting peripheral blood mononuclear cells (PBMCs) from a patient via leukapheresis. These cells are then pulsed ex vivo with synthetic peptides derived from the melanoma-associated antigen 3 (MAGE-3) and the melanoma antigen recognized by T-cells 1 (Melan-A, also known as MART-1). Upon re-infusion into the patient, the antigen-presenting cells (APCs) within the PBMC population present these epitopes to the endogenous immune system. This presentation is intended to prime and expand a population of cytotoxic T-lymphocytes (CTLs) that specifically recognize and eliminate tumor cells expressing MAGE-3 and Melan-A. This approach aims to bypass immune tolerance and generate a targeted, durable anti-tumor immune response.
- Other names
- MAGE-3 and Melan-A peptide-pulsed autologous peripheral blood mononuclear cellsMAGE3 and Melan-A peptide-pulsed autologous peripheral blood mononuclear cellsMAGE 3 and Melan-A peptide-pulsed autologous peripheral blood mononuclear cellsMAGE-3/Melan-A peptide-pulsed PBMC vaccineautologous MAGE-3/Melan-A peptide-pulsed PBMC vaccine
02
Targets
MART-1/HLA-A*02:01 (Melanoma-associated antigen (Melanoma antigen recognized by T cells 1, Melanocyte protein PMEL, Tyrosinase) peptide-HLA-A*02:01 complex)HLA-A*01 (Human leukocyte antigen A*01:01)
Beyond the preview
Go deeper on MAGE-3 peptide-pulsed autologous peripheral blood mononuclear cells + Melan-A peptide-pulsed autologous peripheral blood mononuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-3 peptide-pulsed autologous peripheral blood mononuclear cells + Melan-A peptide-pulsed autologous peripheral blood mononuclear cells.